Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Liabilities (2020 - 2025)

Historic Other Non-Current Liabilities for UroGen Pharma (URGN) over the last 6 years, with Q3 2025 value amounting to $3.8 million.

  • UroGen Pharma's Other Non-Current Liabilities rose 1869.13% to $3.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.8 million, marking a year-over-year increase of 1869.13%. This contributed to the annual value of $3.8 million for FY2024, which is 1869.13% up from last year.
  • As of Q3 2025, UroGen Pharma's Other Non-Current Liabilities stood at $3.8 million, which was up 1869.13% from $3.8 million recorded in Q2 2025.
  • UroGen Pharma's 5-year Other Non-Current Liabilities high stood at $3.8 million for Q4 2024, and its period low was $2.7 million during Q1 2021.
  • In the last 5 years, UroGen Pharma's Other Non-Current Liabilities had a median value of $3.0 million in 2022 and averaged $3.1 million.
  • In the last 5 years, UroGen Pharma's Other Non-Current Liabilities skyrocketed by 460.07% in 2021 and then skyrocketed by 1869.13% in 2024.
  • Over the past 5 years, UroGen Pharma's Other Non-Current Liabilities (Quarter) stood at $2.8 million in 2021, then rose by 6.19% to $3.0 million in 2022, then grew by 5.83% to $3.2 million in 2023, then grew by 18.69% to $3.8 million in 2024, then changed by 0.0% to $3.8 million in 2025.
  • Its last three reported values are $3.8 million in Q3 2025, $3.8 million for Q2 2025, and $3.8 million during Q1 2025.